Goldman Sachs Lowers Price Target for Pfizer Ahead of Earnings Report

Goldman Sachs has lowered its price target for Pfizer to $26, maintaining a 'hold' rating, as the pharmaceutical company faces challenges including declining Covid product sales and patent losses. The move comes ahead of Pfizer's first-quarter 2026 earnings report, which is expected to highlight the company's progress in stabilizing revenue and advancing its drug pipeline.

By Tyler Bundy Thu, April 30, 2026 at 10:33 AM PDT 4 min read · Yahoo Finance · April 30, 2026, 17:33 UTC

Tickers: $GS $PFE

Topics: Drugmaker Performance Earnings Report Goldman Sachs Pfizer Stock Forecast

Read the full article at Yahoo Finance

More World news

California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC